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PCI pts from the NHLBI Dynamic Registry.
Results: Emergent CABG was required in 17 pts (0.45%). No differences in pre-proce-
dural characteristics including age, gender, disease history, serious non-cardiac disease,
left ventricular function, extent of coronary disease or clinical presentation were present
between emergency CABG pts and others. Only disease in both the left anterior
descending (LAD) and circumflex (LCX) arteries was greater among CABG pts (31.3%
vs. 9.0%, p<0.01). No differences were noted in lesion complexity or number of lesions
attempted. Attempted lesions in either the left main (4.3 vs. 0.5%) or the LCX (47.8 vs.
23.2%), however, were more frequent among pts requiring emergent CABG (p<0.05 for
both comparisons). During PCI, emergency CABG pts more often experienced pro-
longed chest pain, (50.0 vs. 6.8%, p<0.001), unsuccessful angiographic outcome (52.9
vs. 3.1%, p<0.001), major dissection persisting after the procedure (50.0 vs. 0.6%,
p<0.001), side branch occlusion (9.1 vs. 2.2%, p<0.05), persistent flow reduction (45.5
vs. 0.9%, p<0.001) and sustained abrupt closure (27.3 vs. 0.3%, p<0.001). Rates of
death (17.6 vs. 0.3%, p<0.001) and death/MI (29.4 vs. 2.7%, p<0.001) were substantially
higher among emergent CABG pts.
Conclusions: Aside from site of lesion treatment (left main or LCX arteries) and pres-
ence of combined LCX/LAD disease, no pre-procedural features distinguished pts who
experienced emergent CABG. Marked differences were noted after PCI initiation. These
results suggest that accurate identification of pts at low risk for emergent CABG can not
be accomplished accurately in advance of the PCI procedure, and raise concern about
the safety of performing elective PCI in the absence of immediate surgical backup.
4:30 p.m.
852-3 Temporal Variation in Fatal Percutaneous Coronary 
Intervention Outcomes: A Report From the National 
Heart, Lung, and Blood Institute Dynamic Registry
Warren K. Laskey, Faith Selzer, Howard Cohen, David Holmes, Robert Wilensky, David 
Williams, Katherine Detre, The NHLBI Dynamic Registry, National Naval Medical Center, 
Bethesda, MD, University of Pittsburgh, Pittsburgh, PA
Background. The well-known increase in fatal cardiovascular events in the morning
hours has been attributed to a circadian variation in the substrate for myocardial ischemia
and coronary thrombosis. We hypothesized that this time-dependent predisposition to
fatal cardiovascular events might be reflected in a similar variation in PCI outcomes
Methods. We analyzed fatal in-hospital PCI outcomes in 6,395 patients in the Dynamic
Registry undergoing PCI between 0800 and 2000 hours. This sample was divided into
three evenly- populated groups ( T1: 0800-1100 hrs, n= 2,237; T2: 1101-1400 hrs, n=
2,146; T3: 1401-2000 hrs, n= 2,012). Inter-group raw mortality rates and mortality rates
following adjustment for demographic, clinical, angiographic and procedural covariates
were analyzed.
Results. Inter-group differences in the frequency of important covariates and unadjusted
mortality were found (Table). 
After adjusting for confounders, including severity of presentation, T3 was associated
with a two-fold higher risk of death (Odds Ratio 1.98; 95% CI 1.04,3.85) when compared
to T2. Furthermore, a significant (p=0.04) U-shaped relationship between mortality and
time was noted.
Conclusions. The risk of PCI-related mortality appears lowest in mid-day, is somewhat
higher in the morning and highest in the late afternoon. While this pattern is consistent
with the variation noted in spontaneous cardiovascular events, the increased risk associ-
ated with procedures performed later in the day remains unexplained.
4:45 p.m.
852-4 The Effects of Treatment Delay in Patients Transferred 
for Primary Percutaneous Coronary Intervention for ST-
Segment Elevation Myocardial Infarction
David Shavelle, M. Leila Rasouli, Paul D. Frederick, C. Michael Gibson, William J. 
French, Harbor-UCLA Medical Center, Torrance, CA
Background: Hospital transfer is a strong independent predictor of delay for treatment in
patients receiving primary percutaneous coronary intervention (PPCI) for ST segment
elevation myocardial infarction (STEMI).Despite the lack of positive data from random-
ized trials, transfer of patients is widely practiced. Our aim was to determine the outcome
of patients being transferred for PPCI and evaluate whether mortality is related to door-
to-balloon times.
Methods: Patients presenting within 12 hours with STEMI and undergoing transfer for
PPCI were identified from the National Registry of Myocardial Infarction database (NRMI
2, 3 and 4, n=7133). The short-term outcome of those that received early (<2 hours) was
compared to those that received delayed (>2 hours) PPCI using multivariate logistic
regression analyses and propensity score methodology.
Results: Patients receiving early PPCI (n=1062) were younger, more likely to be males
and smokers, have less of a cardiac history (prior angioplasty and bypass surgery) and
less likely to have diabetes than those that receiving delayed PPCI (n=6071). The door-
to-balloon time (mins, mean+std dev) for the early PPCI compared to the late PPCI group
was 99+16 vs 264+178, respectively (p<0.0001). The early PPCI group had less recur-
rent ischemia and angina (5.8% vs. 10.1%,p<0.001), less cardiogenic shock (5.1% vs
8.9%,p<0.001) and a shorter length of hospital stay (4.4+3.5 vs 5.4+4.7, p<0.001). In
hospital mortality was lower for the early vs late PPCI group (2.7% vs. 6.2%,p<0.001;
entire cohort 5.7%). Comparing patients matched on propensity score (n=994) showed
mortality was lower in the early vs delayed PPCI group (2.6% vs 4.7%, c statistic 0.652).
Conclusions: Less than 15% of patients who received PPCI were treated within the rec-
ommended ACC/AHA guidelines of 90+30 minutes. Door-to-balloon times of less than 2
hours in patients undergoing transfer for PPCI is associated with a significant reduction in
short term mortality suggesting that efforts must be made to reduce delays during trans-
fer.
ORAL CONTRIBUTIONS
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Drug-Eluting Stents: Clinical Experience
Wednesday, March 10, 2004, 8:30 a.m.-10:00 a.m.
Morial Convention Center, La Nouvelle B
8:30 a.m.
862-1 Matched Comparison of Direct Stenting to Predilation 
With the Sirolimus-Eluting Bx VelocityTM Stent
Jeffrey W. Moses, Martin B. Leon, Jeffrey J. Popma, Sidney A. Cohen, Richard E. Kuntz, 
Lenox Hill Hospital, New York City, NY
Background: Direct stenting may lead to improved outcomes due to reduced arterial
injury, the avoidance of abrupt vessel closure, and reduced procedural time and materi-
als. Non-randomized data supporting this hypothesis is available from patients who were
treated with direct stenting vs. those who received pre-dilation from NEW SIRIUS (pooled
E-SIRIUS and C-SIRIUS trials). While procedural success was 98.2% for both groups,
outcomes in patients treated with direct stenting vs. pre-dilation suggested improved
results with direct stenting, including freedom from target lesion revascularization (95.1%
vs. 98.3%; p = ns) and improvement in in-stent late loss (0.11 +/- 0.32 mm vs. 0.20 +/-
0.38 mm; p = ns) measured at 270 days.
Methods: In order to test this hypothesis, 225 patients were enrolled at sixteen sites in
the United States from April 3, 2003 to June 23, 2003 and received Sirolimus-eluting
stents using a strategy of direct stenting. Enrollment inclusion and exclusion criteria
matched those of the pivotal US SIRIUS trial. The primary endpoint in this trial is in-lesion
late loss at 8 months. Additional 8 month post-procedure clinical and angiographic end-
points include the individual components of and the composite of major adverse cardiac
events (MACE), angiographic binary restenosis, delivery strategy success, and proce-
dure time. Outcomes will be compared to matched paired patients from the sirolimus arm
of the pivotal US SIRIUS trial.
Results: Patient demographics, procedural outcomes, and 30 day clinical outcomes will
be presented. Eight month angiographic and clinical outcomes will be completed by Feb-
ruary 2004 and these 8 month outcomes data presented.
Conclusion: Procedural outcomes, 30 day clinical outcomes, and 8 month clinical and
angiographic outcomes from the DIRECT trial will be compared with outcomes from a
matched group from the US SIRIUS trial.
8:45 a.m.
862-2 Sirolimus-Eluting Stent Implantation in Routine Clinical 
Practice: A 12-Month Follow-Up Report From the 
International eCYPHER Registry
Chaim Lotan, E. Sousa, Philip Urban, Anthony Gershlick, Joachim Schofer, Giulio 
Guagliumi, Philippe Guyon, Christophe Tournay, The e-CYPHER Investigators, 
Hadassah University Hospital, Jerusalem, Israel
Background/Methods: Sirolimus-eluting stents (SES) effectively reduce the rate of in
stent restenosis and target vessel revascularization in patients with de novo coronary
artery lesions shown already in 4 multi-centre randomized trials. To replicate the results
in routine clinical practice, ( Europe, Latin America, Asia Pacific,the Middle East =368
sites), 8,211 patients (August 2003) with at least 1 CYPHER SES were consecutively
enrolled in e-CYPHER, an independent ongoing Internet-based registry, since April
2002.
Results: Six-month follow-up results: The mean age of the entire cohort was 61.9 ± 11.30
years, 6,350 patients (77.3%) were male, 2,385 (29.1%) were diabetics, and 4,624
patients (56.3%) had multi-vessel disease. Indication for revascularization was stable
angina in 3,317 (40.4%), unstable angina in 2,790 (34.0%) and recent MI (<72 hours) in
618 (7.5%) patients. 9885 lesions were treated (1.20 lesions/patient), 8411 lesions
(85.1%) were de novo, and 227 (2.3%) were in bypass grafts, 179 (1.9%) were in the left
main stem (106 unprotected and 73 post-CABG), and 286 (2.9%) were chronic total
occlusions. Mean target vessel reference diameter was 2.8 ± 0.35 mm, and mean lesion
length 17.3 ± 9.03 mm. The majority of lesions were treated with one SES, but 1,171
(11.8%) lesions were treated with multiple SES, 918 (78.4%) of which had overlapping
stents. Overall, 1.10 ± 0.40 stents/lesion were implanted. The in-hospital MACE rate was
0.83% (0.19% death, 0.19% AMI, 0.39% repeat PCI (TLR) and 0.06% TV-CABG). The
SAT (reported and attributable events) rate of 0.34% is comparable to that reported in the
controlled clinical trial population and to that reported with bare metal stents.
Conclusions: These results, collected from the largest single registry of drug-ES, reflect
the usage patterns of the CYPHER stent in routine clinical practice. They confirm the fea-
Characteristic T1 (%) T2 (%) T3 (%) p (overall)
Acute coronary syndrome 60.2 67.5 76.9 < 0.001
Urgent/emergent 33.0 37.7 50.8 < 0.001
No. of significant lesions 3.03 2.95 2.84 <0.01
Mortality 1.0 0.7 1.7 < 0.01
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sibility of data collection through the Internet as a post marketing surveillance tool. In-
hospital MACE rates are low, and comparable to those observed in the clinical trials.
Comprehensive 12-month clinical follow-up will be available at the time of presentation.
9:00 a.m.
862-3 Subacute Stent Thrombosis After Successful Placement 
of Sirolimus-Eluting Coronary Stents: Real-World 
Experience
Allen Jeremias, Jonathan Bridges, Brian Bigelow, Brett Sylvia, Kalon K. Ho, Duane S. 
Pinto, David J. Cohen, Donald E. Cutlip, Joseph P. Carrozza, Jr., Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, MA
Background: Subacute stent thrombosis (SAT) is a rare but devastating complication of
intracoronary stent implantation. The incidence with potent anti-platelet therapy has been
reported to be between 0.5-1.9%. Recently, the sirolimus-eluting Cypher™ stent was
introduced in the US. The randomized SIRUS trial reported a 0.4% rate of SAT. However,
the Food and Drug Administration has received 47 reports of SAT that occurred in clinical
practice and the manufacturer has subsequently issued a warning letter. The aim of this
study was to evaluate the incidence and potential risk factors of SAT in patients receiving
the sirolimus-eluting stent outside of clinical trials.
Methods: Since the commercial introduction of Cypher™ stents to the US in April 2003,
all patients that received sirolimus-eluting stents at our institution were followed in a reg-
istry. Percutaneous coronary intervention was performed using standard techniques. All
patients were treated with aspirin pre- and clopidogrel or ticlopidine immediately post-
procedure. The primary endpoint of the study was the incidence of SAT at 30 days.
Results: A total of 456 patients underwent implantation of 608 sirolimus-eluting stents.
The mean stent diameter was 2.8±0.3 mm and the mean stent length was 19.7±5.7 mm.
There were no cases of SAT during the index hospitalization, with 4 cases reported after
discharge during the first 30 days post-stenting (mean onset 9±4 days). There was no
apparent difference in stent diameter (2.6±0.2 mm) or stent length (19.7±6.1 mm)
between patients with SAT and the rest of the population. Three of the 4 patients discon-
tinued anti-platelet therapy after hospital discharge and in one patient the sirolimus-elut-
ing stent was implanted in the setting of an acute myocardial infarction.
Conclusion: Even in ‘real world’ patients, the incidence of SAT after sirolimus-eluting
stent implantion is less than 1%, and within the expected range for bare metal stents. The
discontinuation of anti-platelet therapy appears to be the most important risk factor for the
development of SAT.
9:15 a.m.
862-4 Comparative Incidence of Angiographically Proven 
Early Stent Thrombosis in Unselected Sirolimus- and 
Paclitaxel-Eluting Stent Populations
Andrew T. L Ong, Pedro A. Lemos, Angela Hoye, Chourmouzios A. Arampatzis, 
Francesco Saia, Jiro Aoki, Carlos van Mieghem, Sjoerd H. Hofma, Pieter C. Smits, 
Willem J. van der Giessen, Georgios Sianos, Eugene McFadden, Pim de Feyter, Patrick 
W. Serruys, Thoraxcenter, Rotterdam, The Netherlands
Background:The true incidence of early stent thrombosis after sirolimus or paclitaxel-elut-
ing stent (PES) implantation in an unselected group is at present controversial. So far,
there has been no systematic collection of data to examine its true incidence in the real-
world setting.
Aim: To compare the real-world, tertiary referral institution incidence of angiographic
stent thrombosis in both sirolimus-eluting stents (SES) and PES with historical controls.
Method: Since April 2002, drug eluting stents (DES) have been the default strategy in
patients undergoing percutaneous coronary intervention at our institution. 1000 consecu-
tive patients treated with SES and 500 consecutive patients treated with PES were
defined as our sample population. The last 500 consecutive patients exclusively treated
with bare stents form our control group. Clopidogrel use was as follows: at least one
month following bare stent implantation, at least 3 months following SES implantation,
and at least 6 months following PES implantation. Early stent thrombosis is defined as
stent thrombosis occurring < 30 days after stent implantation.
Results: In our cohort, the incidences of early stent thrombosis are as follows: 
Conclusion: This is the first study to demonstrate that both SES and PES are safe and
are comparable to historical bare stent controls in the real world population of unselected
patients. There appears to be no statistical difference in the incidence of early stent
thrombosis in both DES groups.
9:30 a.m.
862-5 Late Four-Year Follow-Up From the First-in-Man 
Experience After Implantation of Sirolimus-Eluting 
Stents
J. Eduardo Sousa, Alexandre Abizaid, Marco A. Costa, Amanda Sousa, Fausto Feres, 
Luiz A. Mattos, Ibraim Pinto, Ana C. Seixas, Luiz F. Tanajura, Robert Falotico, Jeffrey 
Popma, Patrick W. Serruys, Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil
Background: Short-term (4-months) and intermediate-term (2-year) results after implan-
tation of sirolimus-eluting (Cypher™) stent in human coronary arteries have been
reported. Between 4 to 24 months intimal hyperplasia was consistently suppressed as
assessed by follow-up MLD that showed minimal changes, and IVUS percent obstruction
volume that increased minimally from 0.3±0.8% to 3.3±8.4%. The aim of this study is to
determine if deleterious pathobiologic responses are present after a long (4-year) follow-
up.
Methods: Thirty patients treated with Cypher™ stents for single de novo coronary
lesions (15 fast-release and 15 slow-release formulation) will complete 4-year follow-up
in February, 2004. Clinical follow-up and stress test will be performed in all patients.
Results: At present (45±2 months) there has been 3 cardiac events: one pt presented
with acute MI at 14 months due to non-target site coronary occlusion proximal to the
Cypher™ stent. Serial IVUS interrogation of this MI culprit lesion demonstrated plaque
progression with echo-lucent zones suggesting plaque instability. Another pt with a
patent Cypher™ at mid circumflex developed left main disease and was referred to
bypass surgery (non-TLR) and the third patient presented with lesion progression at the
proximal edge of a Cypher™ stent implanted at a proximal RCA two years after the index
procedure. This pt was treated with another Cypher™ (TLR). Therefore, for the entire
patient cohort, the event free survival of major cardiac events is 90%.
Conclusion: Thusfar, in the FIM experience, the sirolimus-eluting Cypher™ stent has
demonstrated safety and efficacy up to 45-month follow-up, with low rates of major car-
diac events. The complete 4-year follow-up results (available for presentation) should
definitively establish long-term safety and efficacy of SES.
9:45 a.m.
862-6 Stents Without Restenosis: Enough to Replace Bypass 
Surgery?
Huw Griffiths, Ameet Bakhai, Douglas West, Anthony De Souza, Jonathan Clague, 
Simon Davies, Carl Brookes, Andrew Bishop, John Pepper, Carlo Di Mario, Royal 
Brompton Hospital, London, United Kingdom
Background: Drug eluting stents (DES) have been shown to have very low restenosis
across a range of lesion subtypes. We tested the hypothesis that their implementation
would permit a cost effective percutaneous approach to a majority of patients with multi-
vessel disease.
Methods: Two experienced interventionalists reviewed the preoperative coronary angio-
grams of 209 patients undergoing their first coronary bypass operation (CABG) for multi-
vessel disease without other adjunctive surgical procedures at the Royal Brompton
Hospital in 2002. They were classified according to the technical feasibility and complete-
ness of percutaneous revascularisation (PCI) and a provisional strategy was declared. A
cost decision-analysis model with simulated 1 year costs was constructed with a cost of
DES at $3,360.
Results: Mean age was 64.6±8.9 years with 54 diabetics (25.8%). Each patient received
at least 1 arterial graft and a mean of 3.0±0.8 distal anastomoses. Mean post-CABG stay
was 8.9±7.2 days and total cost $22,653. Adequate PCI was judged to be unachievable
in the presence of at least 1 unfavourable total occlusion (CTO) (excessive length,
unfavourable take-off, poor visualisation of the distal vessel) subtending viable myocar-
dium in 48 patients (23%) and extreme tortuosity or calcification in 4 patients (2%). PCI
of grafted major epicardial vessels was anticipated to be complete in 138 patients (66%)
and partial but acceptable in 19 patients (9.1%). Stenting of the left main, “favourable”
CTO, bifurcations or in an ostial location were required in 32 (20.4%), 60 (38.2%), 77
(49.0%) and 74 (47.1%) respectively of cases treated. 3.6±1.4 stents of total length
72.6±37.3 mm were required to treat 3.3±1.2 lesions per patient at an estimated cost of
$22,206. One year repeat revascularisation at an assumed rate of 15% in the PCI group
resulted in a $2,250 cost excess for PCI.
Conclusions: PCI is feasible for a majority of patients undergoing multivessel CABG
with marginally lower hospital cost ($446). It demands however, the use of multiple long
stents and frequent treatment of challenging lesion subtypes. At current DES cost, PCI is
likely to remain more expensive than CABG during long term follow up.
Incidence of Early Stent Thrombosis
Bare stent SES PES p value
Incidence 5/ 500 9/ 1000 5/ 500
Percentage 1.0% 0.9% 1.2% p=0.9
